For research use only. Not for therapeutic Use.
MK-8876（Cat No.:I008079）is an investigational small molecule inhibitor developed by Merck, primarily studied for its potential use in cancer therapy. It targets and inhibits the protein kinase checkpoint kinase 1 (CHK1), a key regulator of the DNA damage response and cell cycle. By inhibiting CHK1, MK-8876 disrupts the ability of cancer cells to repair DNA damage, leading to increased cell death, particularly in rapidly dividing tumor cells. Preclinical studies suggest it may enhance the efficacy of DNA-damaging agents like chemotherapy and radiation. MK-8876 is being explored in clinical trials for various cancers.
| Catalog Number | I008079 |
| CAS Number | 1426960-33-9 |
| Synonyms | MK-8876; MK 8876; MK8876.;2-(4-Fluorophenyl)-5-(11-fluoro-6H-pyrido[2/’,3/’:5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-3-benzofurancarboxamide |
| Molecular Formula | C32H24F2N4O5S |
| Purity | ≥95% |
| Target | HCV NS5B Site D Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 5-(15-fluoro-8-oxa-3,10-diazatetracyclo[8.7.0.02,7.011,16]heptadeca-1(17),2(7),3,5,11(16),12,14-heptaen-4-yl)-2-(4-fluorophenyl)-N-methyl-6-[methyl(methylsulfonyl)amino]-1-benzofuran-3-carboxamide |
| InChI | InChI=1S/C32H24F2N4O5S/c1-35-32(39)29-21-13-20(25(37(2)44(3,40)41)15-28(21)43-31(29)17-7-9-18(33)10-8-17)23-11-12-27-30(36-23)26-14-19-22(34)5-4-6-24(19)38(26)16-42-27/h4-15H,16H2,1-3H3,(H,35,39) |
| InChIKey | GOHCXBUFLQKEIO-UHFFFAOYSA-N |
| SMILES | CNC(=O)C1=C(OC2=CC(=C(C=C21)C3=NC4=C(C=C3)OCN5C4=CC6=C5C=CC=C6F)N(C)S(=O)(=O)C)C7=CC=C(C=C7)F |
| Reference | </br>Process Development of the HCV NS5B Site D Inhibitor MK-8876 Michael J. Williams†, Qinghao Chen*†, Lorenzo Codan§, Renee K. Dermenjian†, Spencer Dreher†, Andrew W. Gibson‡, Xianliang He∥, Yan Jin†, Stephen P. Keen‡, Alfred Y. Lee†, David R. Lieberman‡, Wei Lin∥, Guiquan Liu∥, Mark McLaughlin†, Mikhail Reibarkh†, Jeremy P. Scott‡, Sophie Strickfuss‡, Lushi Tan†, Richard J. Varsolona†, and Feng Wen∥ † Department of Process Research and Development, Merck Research Laboratories, Rahway, New Jersey 07065, United States ‡ Department of Process Chemistry, Merck Sharp & Dohme Ltd., Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom § Werthenstein BioPharma GmbH (MSD Switzerland), Industrie Nord 1, CH-6105 Schachen, Switzerland ∥ WuXi AppTec Co., Ltd., No. 1 Building, #288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131, China Org. Process Res. Dev., 2016, 20 (7), pp 1227–1238 DOI: 10.1021/acs.oprd.5b00405 Publication Date (Web): January 25, 2016 Copyright © 2016 American Chemical Society |
